Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Studies in mouse models and early human research of low ... as we've shown in the Phase 1b that even efficacy in the range of Dupixent, the standard of care currently, would also be a very ...

After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

AI company Sesame has released the base model that powers Maya, the impressively realistic voice assistant. The model, which is 1 billion parameters in size (“parameters” referring to ...

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...